Literature DB >> 17630173

Bilateral cornual abscess after endometrial ablation following Essure sterilization.

Nicoline E Jansen1, Michel P H Vleugels, Kirsten B Kluivers, Mark E Vierhout.   

Abstract

Endometrial ablation is used extensively to treat dysfunctional bleeding. Since the introduction of Essure tubal sterilization, this permanent contraception method has been widely used. Both endometrial ablation and Essure sterilization are procedures reported to have only a few complications. We describe a serious infectious complication shortly after an endometrial ablation in a patient with Essure microinserts in situ. To our knowledge, this complication has not been reported before in patients with Essure microinserts in situ. We suggest administering prophylactic antibiotics before endometrial ablation in women with Essure microinserts in situ.

Entities:  

Mesh:

Year:  2007        PMID: 17630173     DOI: 10.1016/j.jmig.2007.03.003

Source DB:  PubMed          Journal:  J Minim Invasive Gynecol        ISSN: 1553-4650            Impact factor:   4.137


  4 in total

1.  Incidence of opioid-managed pelvic pain after hysteroscopic sterilization versus laparoscopic sterilization, US 2005-2012.

Authors:  Mitchell M Conover; Jennifer O Howell; Jennifer M Wu; Alan C Kinlaw; Nabarun Dasgupta; Michele Jonsson Funk
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-03-31       Impact factor: 2.890

2.  Appendicitis and uterine abscess: presentation of an unusual fistula between the gynaecological and gastrointestinal tracts.

Authors:  Sian Ruth Parsons; Joanne Elizabeth Bennett; Philip Kaloo; Mike Scott
Journal:  BMJ Case Rep       Date:  2012-09-14

3.  Global endometrial ablation in the presence of essure® microinserts.

Authors:  Diana Aldape; Scott G Chudnoff; Mark D Levie
Journal:  Rev Obstet Gynecol       Date:  2013

4.  Hysterosalpingogram: an essential examination following Essure hysteroscopic sterilisation.

Authors:  V Shah; N Panay; R Williamson; A Hemingway
Journal:  Br J Radiol       Date:  2010-12-01       Impact factor: 3.039

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.